Intravenous Lidocaine Infusion in Lumbar Fusion Surgery
Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Opioid Consumption and Recovery After Lumbar Fusion Surgery: A Randomized Controlled Trial
- Lumbar Fusion Surgery
At a glance
- Phase
- Phase not stated
- Study type
- Interventional
- Sponsor
- Ankara City Hospital Bilkent
- Enrolment target
- 110
- Started
- 1 April 2026
- Main results due
- 1 January 2027
- Study sites
- 1
- Registry updated
- 25 September 2026
Can you take part?
- Aged 18 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * Age ≥18 years * Scheduled for elective lumbar fusion surgery under general anesthesia * American Society of Anesthesiologists (ASA) physical status I-III * Ability to provide written informed consent Exclusion Criteria: * Refusal to participate in the study * ASA physical status ≥IV * Body mass index \>35 kg/m² * Known allergy or hypersensitivity to lidocaine or study medications * Severe cardiac, hepatic, or renal disease * Pregnancy * Neurological disorders affecting pain assessment * Chronic opioid use * Use of opioids or antiemetic drugs before surgery * Inability to cooperate with postoperative assessments
What this study is about
In the sponsor’s own words, from the registry.
Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.
This randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.
The primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.
Study sites(1)
Ankara Bilkent City Hospital
Ankara, Turkey (Türkiye)
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07488832. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me